Shots:

• The P-III FIDELIO-DKD study involves assessing of Finerenone (10/20mg- qd) + SOC vs PBO + SOC in ~ 5-700 patients with CKD and T2D at 1-000+ sites across 48 countries globally
• The study resulted in meeting its 1EPs i.e- delayed the progression of CKD by reducing the combined risk of time to the first occurrence of kidney failure- decrease eGFR ≥40% from baseline @4wks.- or renal death
• Finerenone is an investigational non-steroidal- selective mineralocorticoid receptor antagonist demonstrating risk reduction in renal and cardiovascular events in patients with CKD and T2Dand has received the US FDA’s FT designation in 2015. The company is also evaluating the therapy to reduce CV morbidity and mortality in ~ 7-400 patients with CKD and T2D across 48 countries including the EU- Japan- China- and the US

Click here to read full press release/ article | Ref: Bayer | Image: Business Standard